Allergy, Pulmonary, and Critical Care Medicine, Madison, WI Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2013
NCT01947946
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Allergy, Pulmonary, and Critical Care Medicine 600 Highland Avenue; Madison, WI | Allergy, Pulmonary and Critical Care Medicine, Clinical Science Center 600 Highland Ave, Madison, WI USA

Active Ingredients

Drugs in Phase 3 Trials (1)

benralizumab (fasenra) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1